Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Restored expression of vitamin D receptor and sensitivity to 1,25-dihydroxyvitamin D3 in response to disrupted fusion FOP2-FGFR1 gene in acute myeloid leukemia cells.

Marchwicka A, Corcoran A, Berkowska K, Marcinkowska E.

Cell Biosci. 2016 Feb 2;6:7. doi: 10.1186/s13578-016-0075-9. eCollection 2016.

2.

A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.

Raymond A, Liu B, Liang H, Wei C, Guindani M, Lu Y, Liang S, St John LS, Molldrem J, Nagarajan L.

Oncotarget. 2014 Dec 30;5(24):12675-93.

3.

Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect.

Fan J, Kang HB, Shan C, Elf S, Lin R, Xie J, Gu TL, Aguiar M, Lonning S, Chung TW, Arellano M, Khoury HJ, Shin DM, Khuri FR, Boggon TJ, Kang S, Chen J.

J Biol Chem. 2014 Sep 19;289(38):26533-41. doi: 10.1074/jbc.M114.593970. Epub 2014 Aug 7.

4.

Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.

Tiong KH, Mah LY, Leong CO.

Apoptosis. 2013 Dec;18(12):1447-68. doi: 10.1007/s10495-013-0886-7. Review.

5.

SYK regulates mTOR signaling in AML.

Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.

Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.

6.

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.

Chase A, Bryant C, Score J, Haferlach C, Grossmann V, Schwaab J, Hofmann WK, Reiter A, Cross NC.

Haematologica. 2013 Mar;98(3):404-8. doi: 10.3324/haematol.2012.067959. Epub 2012 Aug 8.

7.

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

Chase A, Bryant C, Score J, Cross NC.

Haematologica. 2013 Jan;98(1):103-6. doi: 10.3324/haematol.2012.066407. Epub 2012 Aug 8.

8.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT.

Nat Med. 2012 Jul;18(7):1118-22. doi: 10.1038/nm.2819.

9.

Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.

Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, Chen GZ, Boggon TJ, Lonial S, Fu H, Khuri FR, Kang S, Chen J.

Mol Cell. 2011 Dec 23;44(6):864-77. doi: 10.1016/j.molcel.2011.10.015.

10.

Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells.

Fan J, Hitosugi T, Chung TW, Xie J, Ge Q, Gu TL, Polakiewicz RD, Chen GZ, Boggon TJ, Lonial S, Khuri FR, Kang S, Chen J.

Mol Cell Biol. 2011 Dec;31(24):4938-50. doi: 10.1128/MCB.06120-11. Epub 2011 Oct 3.

11.

Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Ren M, Qin H, Ren R, Tidwell J, Cowell JK.

Cancer Res. 2011 Dec 1;71(23):7312-22. doi: 10.1158/0008-5472.CAN-11-1109. Epub 2011 Sep 21.

12.

Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.

Ren M, Cowell JK.

Blood. 2011 Jun 23;117(25):6837-47. doi: 10.1182/blood-2010-07-295725. Epub 2011 Apr 28.

13.

A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB.

Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, Roger C, Dusanter-Fourt I, Varin-Blank N, Cao A, Metelev V, Baran-Marszak F, Fagard R.

BMC Cell Biol. 2011 Apr 12;12:14. doi: 10.1186/1471-2121-12-14.

14.

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM.

Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.

15.

Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling.

Pighi C, Gu TL, Dalai I, Barbi S, Parolini C, Bertolaso A, Pedron S, Parisi A, Ren J, Cecconi D, Chilosi M, Menestrina F, Zamò A.

Cell Oncol (Dordr). 2011 Apr;34(2):141-53. doi: 10.1007/s13402-011-0019-7. Epub 2011 Mar 11.

16.

Targeting mutant fibroblast growth factor receptors in cancer.

Greulich H, Pollock PM.

Trends Mol Med. 2011 May;17(5):283-92. doi: 10.1016/j.molmed.2011.01.012. Epub 2011 Mar 1. Review.

17.

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer.

Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W.

Nucleic Acids Res. 2010 Nov;38(20):6985-96. doi: 10.1093/nar/gkq579. Epub 2010 Jun 29.

18.
19.

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J.

Sci Signal. 2009 Nov 17;2(97):ra73. doi: 10.1126/scisignal.2000431.

20.

Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Kasyapa C, Gu TL, Nagarajan L, Polakiewicz R, Cowell JK.

Proteomics. 2009 Aug;9(16):3979-88. doi: 10.1002/pmic.200800852. Erratum in: Proteomics. 2009 Nov;9(21):5001. Natarajan, Lalitha [corrected to Nagarajan, Lalitha].

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk